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Hospital infections are important health problems in all over the world, because
of their high morbidity and mortality, and prolonging the time of hospitalization
and increasing the cost of treatment. Pseudomonas aeruginosa (P. aeruginosa)
is recognised as one of the leading causes of severe hospital-acquired infections.
P. aeruginosa exhibits high-level resistance to many antimicrobials, and resis-
tance can develop during therapy. Combination antibiotic treatment is preferred
to provide larger spectrum antimicrobial effect and to prevent the rapid emergence
of resistance in nosocomial infections caused by P. aeruginosa. Combinations
usually comprise an anti-pseudomonal beta-lactam and an aminoglycoside or a
fluoroquinolone.
1
The aim of this study was to determine the in vitro effects of some antimi-
crobial drug combinations on multidrug resistant P. aeruginosa strains and
compare them with the susceptible P.aeruginosa strains.
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Purpose: Combination antibiotic treatment is preferred in nosocomial infections caused by Pseudomonas
aeruginosa (P. aeruginosa). In vitro synergism tests were used to choose the combinations which might be used in
clinic. The aim of this study was to investigate the synergistic efficacy of synergistic antibiotic combinations in
multidrug resistant P. aeruginosa strains. Materials and Methods: Synergistic efficacies of ceftazidime-tobramycin,
piperacillin/tazobactam-tobramycin, imipenem-tobramycin, imipenem-isepamycin, imipenem-ciprofloxacin and
ciprofloxacin-tobramycin combinations were investigated by checkerboard technique in 12 multiple-resistant and
13 susceptible P. aeruginosa strains. Results: The ratios of synergy were observed in ceftazidime-tobramycin and
piperacillin/tazobactam-tobramycin combinations as 67%, and 50%, respectively, in resistant strains, whereas
synergy was not detected in other combinations. The ratios of synergy were observed in ceftazidime-tobramycin,
piperacillin/tazobactam-tobramycin, imipenem-tobramycin, imipenem-ciprofloxacin and imipenem-isepamycin
combinations as 31%, 46%, 15%, 8%, 8%, and respectively, in susceptible strains, whereas synergy was not
detected in ciprofloxacin-tobramycin combination. Antagonism was not observed in any of the combinations.
Conclusion: Although the synergistic ratios were high in combinations with ceftazidime or piperacillin/tazobactam
and tobramycin, the concentrations in these combinations could not usually reach clinically available levels. Thus,
the solution of the problems caused by multiple resistant P. aeruginosa should be based on the prevention of the
development of resistance and spread of the causative agent between patients. 
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Bacterial isolates
Study isolates were chosen from  nosocomial P. aeruginosa
isolates collected from January 1996 through August 2000
from the Clinical Microbiology Laboratory of Trakya
University Hospital in Edirne, Turkey. A total of 25 non-
duplicate isolates were included in the study. Twelve of
them were multidrug resistant and 13 of them were suscep-
tible to antimicrobial agents. Strains resistant to ureido-
penicillin, third generation cephalosporin, azteronam,
quinolone, carbapenem and at least two aminoglicosides
were accepted as multidrug resistant. The isolates were
cultured from urine (7 isolates), lower respiratory tract (6
isolates), blood (6 isolates) and skin-soft tissues (6 isolates).
P. aeruginosa ATCC 27853 was included as a quality
control strain. The isolates were stored at -70˚C and studied
after being subcultured twice on blood and EMB agar
(Diomed, Istanbul, Turkey). All strains were identified by
the conventional methods and confirmed by API 20 NE
(Bio Mérieux, Marcy I’Etoile, France).
Antimicrobial agents
Antibiotic powders were obtained from the manufacturers
as follows: Ceftazidime (Glaxo-Wellcome, Turkey),
piperacillin and tazobactam (Wyeth, Istanbul, Turkey),
imipenem (Merck-Sharp and Dohme, Istanbul, Turkey),
ciprofloxacin (Bayer, Istanbul, Turkey), tobramycin
(Eczaclba l, Istanbul, Turkey) and isepamycin (Schering-
Plough). Stock solutions were prepared using sterile water
and stored at -70˚C until use, with the exception of imi-
penem which was prepared immediately prior to use.
Testing of antimicrobial susceptibility 
Disc diffusion test was performed, by using piperacillin
(100 µg), ceftazidime (30 µg), piperacillin-tazobactam (100
+ 10 µg), sulbactam/sefoperazon (30 + 75 µg), imipenem
(10 µg), ciprofloxacin (5 µg), amikacin (30 µg), gentamicin
(120 µg), netilmicin (30 µg), tobramicin (10 µg) (Oxoid,
Hampshire, England) and isepamycin (30 µg) (Mast,
Merseyside, England) discs, and the result was interpreted
according to Clinical and Laboratory Standards Institute
(CLSI) methodology.
2,3 Breakpoints for isepamycin were
those recommended by Barry, et al.
4 and breakpoints for
cefoperazone-sulbactam were those recommended by the
manufacturer.    
The minimum inhibitory and bactericidal concentrations
(MICs and MBCs) of ceftazidime, piperacillin/tazobactam,
imipenem, ciprofloxacin, tobramycin and isepamycin were
determined by broth microdilution method as described by
CLSI, and CLSI criteria were used in the interpretations of
the results.
4,5 
Serial two-fold dilutions, ranging from 0.125 to 256
µg/mL, for each antibiotics were prepared in cation-adjusted
Mueller Hinton broth (CAMHB). The inoculum was pre-
pared with 2-3 h broth culture of each isolate, adjusted to a
turbidity equivalent to 0.5 McFarland Standard and diluted
in CAMHB to give a final concentration of 5×10
5 CFU/mL
in the test tray. Trays were covered and then incubated for
16-20 h in ambient air at 37˚C. MIC was defined as the
lowest concentration of antibiotic to completely inhibit
visible growth.
MBCs were determined by removing 10 µL samples from
each well, demonstrating no visible growth, and plated
onto separate blood agar plates. After an incubation at
37˚C for 16-20 h, colonies were counted. MBC was defined
as the lowest concentration of antibiotic to have at least
99.9% killing of the initial inoculum.
6
Synergy studies
In-vitro interactions of ceftazidime-tobramycin, piperacillin/
tazobactam-tobramycin, imipenem-tobramycin, imipenem-
isepamycin, imipenem-ciprofloxacin and ciprofloxacin-
tobramycin combinations were investigated by microdilu-
tion checkerboard technique using 96-well microtiter plates
for each combination. 
Serial two-fold dilutions of the antimicrobial agents in
CAMHB were placed alone or in combination in wells and
inoculated with an appropriate bacterial inoculum so that
each well contained approximately 4-5×10
4 CFU/mL.
After incubation at 37˚C for 16-20 h, the MIC was consi-
dered as the well containing the lowest concentrations of
the two drugs in which no visible growth was observed.
Concentrations of  each antimicrobial which were tested in
combination were between 1/4× MIC and 2× MIC.
Growth and sterility controls were also included in each
plate.
7,8
The fractional inhibitory concentrations (FICs) for each
isolate were calculated as the MIC of drug A or B in com-
bination/the MIC of drug A or B alone. The FIC index (Σ
FIC) was calculated by summing the individual FICs
obtained from the two antimicrobial agents. Synergy was
defined as a FIC index of ≤ 0.5, additivity (indifference) by
a FIC index of > 0.5 to ≤ 4 and antagonism by a FIC index
of > 4. The lowest ΣFIC value calculated in the same
plate for one strain and one combination was determined
as ΣFICmin, and the highest ΣFIC value was determined
as ΣFICmax. 
Statistical methods
Statistical analysis of results from checkerboard assay was
performed using the chi-square test. Differences were
considered significant when p≤0.05.
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Resistance patterns of the 12 multidrug resistant strains are
shown in Table 1. Thirteen strains which served as the con-
trol group were susceptible to all of these antimicrobials. 
The results of MIC and MBC testing of the 12 resistant
and 13 susceptible strains are presented in Table 2. The
MBC values were generally equal or one to three times
greater than those of MIC. 
The ratios of synergy were observed in ceftazidime plus
tobramycin and piperacillin/tazobactam plus tobramycin
combinations as 67% and 50%, respectively, in resistant
strains, and synergy was not detected in other combina-
RESULTS
Table 1.Resistance Patterns of the 12 Multidrug Resistant Strains according to Disk Diffusion Testing
Strain 
IPM* PIP
PIP/
ATM OFX CIP* CAZ* CFP CTX CRO AK GM TOB* NET ISP*
no TAZ*
D 1RRSRRRRRRRIRRRS
D 2 RRRRRRRRRRSRSRS
D 3RRSRRRRRRRSRRRS
D 4RRSRRRRRRRIRRRS
D 5 RRRRRRRRRRSRRRS
D 6 RRRRRRRRRRSRS IS
D 7 RRRRRRRRRRRRRRR
D 8 RRRRRRRRRRRRRRR
D 9RRSRRRRRRRRRRRS
D10 R R S R R R R R R R S R R R S
D11 R R S R R R R R R R S R R R S
D12 R R S R R R R R R R S R R R S
Dn, Multidrug resistant strains; IPM, imipenem; PIP, piperacillin; PIP/TAZ, piperacillin/tazobactam; ATM, aztreonam; OFX, ofloxacin; CIP, ciprofloxacin; CAZ 
ceftazidime; CFP, cefoperazone; CTX, cefotaxime; CRO, ceftriaxone; AK, amikacin; GM, gentamicin; TOB, tobramycin; NET, netilmicin; ISP, isepamycin; R,
resistant; S, susceptible; I, intermediate (the intermediate strains are accepted as resistant).
*Also evaluated by MIC determination.
Table 2.MIC and MBC Ranges, and MIC50, MIC90, MBC50, and MBC90Values of the Strains
Resistant strains (n = 12) Susceptible strains (n=13)
Antibiotic MIC (µg/mL) MBC (µg/mL) MIC (µg/mL) MBC (µg/mL)
Range 50% 90% Range 50% 90% Range 50% 90% Range 50% 90%
CAZ 16 - 256 256 256 32 - 256 256 256 0.5 - 4 2 4 1 - 8 2 4
IPM 8 - 32 16 16 16 - 64 16 32 0.25 - 1 1 1 0.5 - 4 1 4
PIP / TAZ 64 - 128 64 128 64 - 256 128 128 2 - 8 4 8 2 - 128 8 32
CIP 8 - 128 32 64 16 - 128 64 64 < 0.125 - 0.25 < 0.125 0.25 0.125 - 0.5 0.25 0.25
TOB 2 - 256 128 128 2 - 256 128 128 0.5 - 1 0.5 1 0.5 - 2 1 1
ISP 4 - 256 16 32 8 - 256 16 32 1 - 4 2 4 2 - 8 2 4
CAZ, ceftazidime; IPM,  imipenem; PIP / TAZ,  piperacillin / tazobactam; CIP,  ciprofloxacin; TOB,  tobramycin;  ISP, isepamycin.
Table 3.Checkerboard Synergy Results for the Different Antimicrobial Combinations      
Drug
Resistant strains Susceptible strains
combination
Synergistic Indifferent Antagonistic Synergistic  Indifferent Antagonistic 
n (%) n (%) n (%) n (%) n (%) n (%)
CAZ-TOB 8 (67) 4 (33) - 4 (31) 9 (69) -
PIP / TAZ-TOB 6 (50) 6 (50) - 6 (46) 7 (54) -
CIP-TOB - 12 (100) - - 14 (100) -
IPM-TOB - 12 (100) - 2 (15) 11 (85) -
IPM-CIP - 12 (100) - 1 (8) 12 (92) -
IPM-ISP - 12 (100) - 1 (8) 12 (92) -
CAZ, ceftazidime; PIP / TAZ, piperacillin / tazobactam; CIP, ciprofloxacin; IPM, imipenem; TOB, tobramycin; ISP, isepamycin.Devrim Dundar and Metin Otkun
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tions. The ratios of synergy were observed in ceftazidime-
tobramycin, piperacillin/tazobactam-tobramycin, imipenem-
tobramycin, imipenem-ciprofloxacin and imipenem-
isepamycin combinations as 31%, 46%, 15%, 8% and 8%,
respectively, in susceptible strains and synergy was not
detected in ciprofloxacin-tobramycin combination. Anta-
gonism was not observed in any of the combinations. The
results of the checkerboard synergy analysis are shown in
Table 3.
Antibiotic concentrations at which synergistic interac-
tions were observed in multidrug resistant strains are
shown in Table 4. Concentrations of ceftazdime and pipe-
racillin/tazobactam which provided synergy in resisant
strains were within clinically achievable limits (under 160
µg/mL for ceftazdime and under 264.4-368 µg/mL for
piperacillin/tazobactam). However, only a few concentra-
tions of tobramycin were in the range of clinically achie-
vable limits (under 16-24 µg/mL).
Multidrug resistance in P. aeruginosa is a serious growing
problem all over the world. Combination therapy is recom-
mended for the treatment of P. aeruginosa infections in
order to ensure synergistic action and decrease the risk of
development of resistance. In vitro synergy tests, including
checkerboard and time-kill methods, are used to determine
the activity of antimicrobial combinations. In spite of some
limitations, the checkerboard technique is simple to per-
form and remains to be a widely used technique to assess
antimicrobial combinations.
8 Comparison of results from
different studies is difficult due to variations in microbio-
logy test materials, methods and synergy definitions.
9
Beta-lactam and aminoglycoside combinations are the
combinations most frequent used for the treatment of P.
aeruginosa infections.
2,10 Synergistic interactions of these
combinations have been reported in many studies.
11-26 In
the present study, we detected synergy only in ceftazidime-
tobramycin (67%) and piperacillin/tazobactam-tobramycin
(50%) combinations in resistant strains, and in ceftazidime-
tobramycin (31%), piperacillin/tazobactam-tobramycin
(46%), imipenem-tobramycin (15%) and imipenem-isepa-
mycin (8%) combinations in susceptible strains. No stati-
stically significant differences in synergy rates were found
between resistant and susceptible strains. However, Chan
reported more synergy in susceptible strains than in resistant
strains.
13 On the other hand, several investigators demons-
trated that synergy rates are not affected by individual
resistance rates of the drugs in combination, similar to our
study.
14,15,17,18
Weiss and Lapointe
11 detected less synergy in imipenem-
tobramycin combination than the other beta-lactam combi-
nations. In our study, synergy was not detected in imipenem-
tobramycin and imipenem-isepamycin combinations in
resistant strains and low synergy rates (15% and 8%,
respectively) were observed in susceptible strains. All of
the resistant strains except two (D2 and D6) were resistant
to tobramycin. In D2, synergy was not detected in any
combinations and, in D6, synergy was detected only in
piperacillin/tazobactam-tobramycin combination. Only
two resistant strains (D7 and D8) were resistant to isepa-
mycin. Synergy with imipenem-isepamycin combination
was observed only in one susceptible strain. It is reported
that synergy rates are high with cephalosporin-isepamycin
combinations, whereas imipenem-isepamycin combination
is less effective.
24 We considered that imipenem resistance
might have affected the occurences of synergy. However,
low resistance rates of  isepamycin did not induce synergy.  
There are many reports in the literature on synergism
with several rates observed with quinolone and beta-lactam
antibiotics.
26-30 In our study, synergy was not demonstrated
in resistant strains with imipenem-ciprofloxacin combi-
nation while synergy was observed in 8% of the susceptible
strains. Combination of aminoglycosides with fluoro-
quinolones rarely shows synergy.
19,28,30,31 We observed
Table 4. Synergistic Antibiotic Concentrations Observed in 
Multidrug Resistant Strains  
Strain no
Concentration (µg/mL)
CAZ - TOB PIP/TAZ - TOB
D1 128 / 128 -
D2 - -
D3 128 / 16 8 / 32
64 / 32 16 / 32
D4 32 / 64
64 / 64
128 / 8
128 / 16
128 / 32 -
D5 128 / 16
128 / 32 -
D6 - 16 / 0.5
32 / 0.25
D7 - -
D8 4 / 64 -
D9 64 / 32 16 / 32
D10 - 16 / 32
D11 32 / 32
64 / 32 16 / 32
D12 - 16 / 32
Dn, Multidrug resistant strains; CAZ, ceftazidime; TOB, tobramycin; PIP / TAZ, 
piperacillin / tazobactam.
DISCUSSIONadditive effect with ciprofloxacin-tobramycin combination
in all of the strains.    
Furthermore, none of the antimicrobial combinations test-
ed in the current study demonstrated antagonism against
any of the isolates tested. 
Beta lactam-aminoglycoside combinations were shown
to be the most effective combinations against P. aeruginosa.
However, clinically achievable plasma concentrations at
customary dosages might be important limitation in the use
of these combinations for providing synergic effects. Mean
peak plasma concentration of ceftazidime (2 g) intravenou-
sly every 6-8 hours has been reported to be 160 µg/mL.
32
This concentration is over the concentrations of ceftazdime
which provided synergy in our study. In beta-lactam
antibiotics, drug concentrations which is over the MIC
values must be maintained constant to reach bactericidal
effect. For this reason, it is not possible to continuously
reach this concentration, because of short half-life of the
drug (two hours). Mean peak plasma concentrations of
tobramycin (5.1 mg/kg and 7 mg/kg every 8 hours) daily
dose have been reported to be 4-10 µg/mL and 16-24 µg/mL,
respectively.
33 Although tobramycin concentrations in which
synergy was observed were with clinically achievable
limits in ceftazidime-tobramycin combination in some
resistant strains, it is highly possible that this combination
is ineffective because ceftazidime concentrations were not
in clinically achievable limits. Similarly, mean peak plasma
concentration of piperacillin/tazobactam (3.375 g every 6
hours) has been reported to be 264.4-368 µg/mL
34 and con-
centrations in which synergy was observed were lower than
this value. However, piperacillin/tazobactam-tobramycin
combination can not be considered as clinically effective in
resistant strains except for D6, because tobramycin concen-
trations were not with clinically achievable limits. On the
other hand, both ceftazidime-tobramycin and piperacillin/
tazobactam-tobramycin combinations can be effective in
urinary tract infections because the drugs are excreted from
the body through the kidney unchanged with higher con-
centrations than serum. All of the synergistic interactions
in susceptible strains were with clinically achievable con-
centrations (data not shown).  
In conclusion, the variability of the results obtained in
several studies may be due to differences in methodology,
definitions of synergy and choice of the strains. Further-
more, there may not be a correlation between in vitro
synergy and clinical efficacy. Therefore, additional in vivo
studies to assess clinical efficacy of combinations are
warranted. Moreover, antibiotic concentrations in syner-
gistic combinations may not always reach clinically availa-
ble levels. Thus, the solution of the problems caused by
multiple resistant P. aeruginosa should be based on the
prevention of development of resistance and spread of
causative agents between patients. 
A part of the study has been reported as a poster presen-
tation in “XII. International Congress of Bacteriology and
Applied Microbiology, 5-9 August 2008, Istanbul”.
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